AI Article Synopsis
- The study evaluated the long-term effects of Azathioprin therapy in 19 patients with progressive systemic sclerosis (PSS), with an average treatment duration of 47 months.
- In 16 patients, the disease showed no signs of progression, particularly in lung and kidney symptoms, while one patient experienced minor deterioration.
- Although two patients died during the study—one from heart failure and the other from complications related to long-term treatment—the overall findings suggest that long-term Azathioprin treatment can significantly slow PSS progression and improve patient outcomes.
Article Abstract
The study presents the results of an Azathioprin long-term therapy in 19 of 60 patients with progressive systemic sclerosis (PSS). Average treatment was 47 months (6 to 114 months). The patients received 2-2,5 Azathioprin/kg bodyweight daily. In 16 cases no further progression of PSS was noted. One patient showed minor deterioration. In particular no further deterioration in the lung and kidney manifestations were found. Two patients died. A female patient showed signs of osteomyelofibrosis after being treated for 70 months. She died 3,5 years after Azathioprin had been discontinued. The second patient died of right heart failure after recurrent pulmonary emboli. On the whole treatment with Azathioprin over a long period of time seems in most cases to hold the progression of the disease. The unfavourable prognosis can therefore be much improved.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!